CRDF
Q4 2026 EPS Estimate
$-0.15
Nov 5, 2026
Revenue Estimate
$67,222
FY2030E EPS$0.70

Analyst Sentiment

Wall St. Consensus
Hold
13 analysts·Moderate coverage
62
Score
7 Buy (54%)5 Hold (38%)1 Sell (8%)
Rating Breakdown
Strong Buy
00%
Buy
754%
Hold
538%
Sell
18%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
+120.1%
Consensus
$2.00
+120.1%
Bull
$2.00
+120.1%
12-Month Target Range13 analysts
$2.00$2.00$2.00
Current $0.91Consensus
Current Price
$0.91
Upside to Consensus
$1.09

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-26.32%
EPS
FY2028
Rev+21.51%
EPS
FY2029
Rev+44033.70%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$256,888$189,286$230,000$102M$308M
Low$88,582$80,547$92,723$41M$124M
High$434,052$293,997$389,440$172M$522M
EBITDA Avg$-256,888$-189,286$-230,000$-102M$-308M
Low$-434,052$-293,997$-389,440$-172M$-522M
High$-88,582$-80,547$-92,723$-41M$-124M
EBIT Avg$-256,888$-189,286$-230,000$-102M$-308M
Low$-434,052$-293,997$-389,440$-172M$-522M
High$-88,582$-80,547$-92,723$-41M$-124M
Net Income Avg$-42M$-44M$-57M$-35M$46M
Low$-49M$-51M$-80M$-66M$10M
High$-35M$-38M$-35M$-8M$88M
EPS Avg$-0.59$-0.64$-0.88$-0.52$0.70
Low$-0.73$-0.76$-1.19$-0.99$0.16
High$-0.53$-0.57$-0.52$-0.12$1.32
Analysts (Rev / EPS)7 / 65 / 46 / 64 / 33 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$67,222$72,222$50,000$50,000$50,000$50,000$133,185$137,975
Low$29,876$36,111$23,684$23,684$23,684$23,684$63,087$65,356
High$112,036$115,555$81,578$81,578$81,578$81,578$217,301$225,117
EBITDA Avg$-67,222$-72,222$-50,000$-50,000$-50,000$-50,000$-133,185$-137,975
Low$-112,036$-115,555$-81,578$-81,578$-81,578$-81,578$-217,301$-225,117
High$-29,876$-36,111$-23,684$-23,684$-23,684$-23,684$-63,087$-65,356
EBIT Avg$-67,222$-72,222$-50,000$-50,000$-50,000$-50,000$-133,185$-137,975
Low$-112,036$-115,555$-81,578$-81,578$-81,578$-81,578$-217,301$-225,117
High$-29,876$-36,111$-23,684$-23,684$-23,684$-23,684$-63,087$-65,356
Net Income Avg$-10M$-9M$-12M$-13M$-14M$-15M$-14M$-18M
Low$-13M$-12M$-22M$-24M$-25M$-27M$-25M$-32M
High$-9M$-8M$-4M$-4M$-4M$-5M$-4M$-6M
EPS Avg$-0.14$-0.14$-0.18$-0.19$-0.20$-0.22$-0.20$-0.26
Low$-0.19$-0.18$-0.32$-0.35$-0.37$-0.39$-0.37$-0.47
High$-0.12$-0.11$-0.06$-0.06$-0.06$-0.07$-0.06$-0.08
Analysts (Rev / EPS)6 / 54 / 52 / 32 / 32 / 32 / 31 / 41 / 4

Earnings Surprises

Recent Analyst Actions

Jun 3, 2026Craig-Hallum
Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum
Target:$2.00
+43.0%from $1.40
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.